These Analysts Slash Their Forecasts On Century Therapeutics After Weak Q2 Results

Century Therapeutics, Inc. IPSC reported weaker-than-expected second-quarter results.

Century Therapeutics posted quarterly loss of 56 cents per share, missing analysts’ expectations for a loss of 54 cents per share. The company’s sales came in $99,000, missing estimates of $1.14 million.

Century Therapeutics shares fell 1.7% to close at $2.85 on Wednesday.

These analysts made changes to their price targets on Century Therapeutics following earnings announcement.

• Chardan Capital cut the price target on Century Therapeutics from $19 to $17. Chardan Capital analyst Geulah Livshits maintained a Buy rating.
• HC Wainwright & Co. lowered the price target on Century Therapeutics from $17 to $13. HC Wainwright & Co. analyst Mitchell Kapoor maintained a Buy rating on the stock.
• EF Hutton analyst Tony Butler, meanwhile, reiterated Century Therapeutics with a Buy and maintained a $16 price target.

Read This Next: Disney, Alibaba And 3 Stocks To Watch Heading Into Thursday